Home Featured Page 274

Featured

Latest

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Nova Mentis Announces Promising Research Results

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of...

Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: UW-Madison Launches Psychedelic Master’s Program; COMPASS Granted 2 Patents

Early Clinical Research History of DMT

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin...

Psychedelic vs. Hallucinogen-What’s in a Name?

1...273274275...306 Page 274 of 306

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Senior Program Director

Nova Mentis Announces Promising Research Results

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of...

Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: UW-Madison Launches Psychedelic Master’s Program; COMPASS Granted 2 Patents

Early Clinical Research History of DMT

PTSF52 – Start Low, Go Slow

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin...

Psychedelic vs. Hallucinogen-What’s in a Name?

EDITOR PICKS

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY